Partnership with patients needs to be the easy choice, which means making consultations smarter rather than longer.
Whether this holds true for ARDS patients needs to be elucidated in prospective studies.
Whether fructose malabsorption is more common in IBS patients needs to be verified.
Thus the titration for optimal VC concentration in human patients needs to be very cautiously performed.
Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis.
The effect of bronchodilators, such as inhaled beta2-agonists, on exercise performance of COPD patients needs to be tested.
However, factors which influence outcome and the optimal way to integrate CRRT into the care of these patients needs to be better defined[1].
The current risk of liver resection in unselected patients needs to be more clearly defined to appreciate the actual risk of new indications.
Pre-treatment loss to follow-up patients needs to be actively tracked and treated to break the chain of transmission in the community.
We believe that the immune system in PKU patients needs to be deeply investigated for its potential clinical relevance.
AUD among TB patients needs to be addressed urgently and the findings suggest the importance of integrating alcohol treatment into TB care.
